Skip to Content

Join the 'CellCept' group to help and get support from people like you.

CellCept News

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the ...

Drug Combo Helps Lupus-Related Kidney Condition

Posted 10 Nov 2014 by Drugs.com

MONDAY, Nov. 10, 2014 – A combination of drugs may offer a better way to combat a serious kidney complication that commonly affects people with lupus, a new study from China suggests. In a trial of more than 300 Chinese patients with the condition, known as lupus nephritis, those who were given a trio of powerful drugs were more likely to see a complete remission. After six months, 46 percent ...

Kidney Transplant Rejection Drugs Tied to Pregnancy Risks in Study

Posted 23 Oct 2013 by Drugs.com

WEDNESDAY, Oct. 23 – Drugs meant to reduce the risk of organ rejection may increase the risk of miscarriage and birth defects when taken by female kidney transplant patients, according to a new study. The drugs – called mycophenolic acid products – reduce the risk of organ rejection by suppressing the immune system. The study included 163 female transplant patients who discontinued ...

FDA Medwatch Alert: CellCept (mycophenolate mofetil) - Feb 12, 2009

Posted 12 Feb 2009 by Drugs.com

[Posted 02/12/2009] FDA and Roche Laboratories notified healthcare professionals of the introduction of a CellCept Medication Guide to provide important safety information in language that patients can easily comprehend. FDA regulations require a pharmacist to distribute a copy of the Medication Guide to every patient who fills a CellCept prescription from this point forward. FDA has also ...

FDA Medwatch Alert: Mycophenolate Mofetil (marketed as CellCept) and Mycophenolic Acid (marketed as Myfortic)

Posted 16 May 2008 by Drugs.com

[Posted 05/16/2008] FDA is aware of reports of infants born with serious congenital anomalies, including microtia and cleft lip and palate, following exposure to mycophenolate mofetil (MMF) during pregnancy. MMF, the active drug substance in CellCept, is an ester of the active metabolite mycophenolic acid (MPA), the active drug substance in Myfortic. In most cases, the mothers were taking MMF ...

FDA Medwatch Alert: CellCept (mycophenolate mofetil) - Oct 29, 2007

Posted 29 Oct 2007 by Drugs.com

[Posted 10/29/2007] Roche and FDA notified healthcare providers that use of CellCept (mycophenolate mofetil) is associated with increased risk of first trimester pregnancy loss and increased risk of congenital malformations, especially external ear and facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidney. Based on postmarketing data ...

FDA Medwatch Alert: CellCept (mycophenolate mofetil) - Feb 22, 2007

Posted 22 Feb 2007 by Drugs.com

Indication: Prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants [Posted 02/22/2007] Roche and FDA notified cardiac transplant healthcare practitioners about a clinical study (Heart Spare The Nephron) that was terminated due to an observed increased incidence of grade IIIA acute rejection in heart transplant patients switched from calcineurin ...

FDA Medwatch Alert: Immunosuppressant Drugs: Required Labeling Changes

Posted 14 Jul 2009 by Drugs.com

Sirolimus (marketed as Rapamune), Cyclosporine (marketed as Sandimmune and generics), Cyclosporine modified (marketed as Neoral and generics), Mycophenolate mofetil (marketed as Cellcept and generics), Mycophenolic acid (marketed as Myfortic)   The FDA is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at ...

FDA Medwatch Alert: CellCept (mycophenolate mofetil), Myfortic (mycophenolate acid)

Posted 10 Apr 2008 by Drugs.com

[Posted 04/10/2008] FDA informed healthcare professionals that the Agency is investigating a potential association between the use of CellCept and Myfortic, medicines used to prevent organ rejection, and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease. PML is a rare disorder that affects the central nervous system usually occurring in patients with ...

Ask a Question

Further Information

Related Condition Support Groups

Nephrotic Syndrome, Organ Transplant - Rejection Prophylaxis

CellCept Patient Information at Drugs.com